Past Busse Lectures

The Busse Lecture series is intended to bring speakers to the School of Pharmacy who have a fundamental research interest combined with a strong knowledge of the industrial pharmaceutical research environment.

Apr 8, 2016

Dr. Mauro Ferrari, PhD
President and CEO, Houston Methodist Research Institute
Director, Institute for Academic Medicine, Houston Methodist Hospital System
Senior Associate Dean & Professor of Medicine, Weill Cornell Medical College

  • Nanomedicine 101 & 102
  • Transport Oncophysics
Apr 30 – May 1, 2015

Dr. Kazunori Kataoka
Professor of Biomaterials, Graduate School of Engineering, University of Tokyo

  • Nanotechnology to Develop "the Magic Bullet" for Targeted Cancer Therapy
  • Targeted Chemo- and Molecular-Therapy by self-Asssembled Supramolecular Smart (SSS) Nanosystems from Funcitonalized Block Copolymers
Dec 12-13, 2013

Dr. Leslie Z. Benet
Professor, Department of Bioengineering & Therapeutic Sciences, Schools of Pharmacy & Medicine – UC-San Francisco

  • Transporters, Enzymes and Transporter-Enzyme Interplay in Predicting Drug Absorption and Disposition
  • A Unifying PK/PD Relationship to Predict Drug Dosing REgimens for NMEs, Validate clinical Biomarkers as Qualified Surrogates and Serve as a Quality PK/PD Model Metric
May 9-10, 2013

Dr. Gordon L. Amidon
Charles R. Walgreen, Jr., Professor of Pharmacy; Professor of Pharmaceutical Sciences, College of Pharmacy, University of Michigan

  • A Century of Conflation, Confusion and Global Warming: Biopharmaceutical Product Standards
  • Improving the Oral Absorption of BCS Class III and IV Drugs
Dec 1-2, 2011

Dr. Donald A. Tomalia
CEO and Founder NanoSynthons, LLC, National Dendrimer & Nanotechnology Center, Mount Pleasant, Michigan

  • Dendrimer-based Drug Delivery, Imaging and nanopharmaceuticals
  • Dentron/Dendrimers: Windo to a New Systematic Framework for Unifying Neuroscience
Oct 7-8, 2010

Dr. James M. Anderson
Department of Pathology, Case Western Reserve University

  • Inflammatory Cell Interactions and th eForeign Body Reaction with Surface-Modified Biomaterials
  • Biomaterial Biocompatibility and Biological Design Criteria: Issues and Perspectives
Oct 22-23, 2009

Dr. Valentino J. Stella
Distinguished Professor of Pharmaceutical Chemsitry, University of Kansas

  • A Case for Prodrugs
  • Drug Release of a Poorly Water Soluble Drug from Microporous Pump Tablets and Pellets with (SBE)TM-β-CD as Both a Soubizer and Osmoagent?
Nov 13-14, 2008

Dr. Kinam Park
Showalter Distinguished Professor of Pharmaceutics, Purdue University

  • Drug Delivery Systems: Macro Issues of Nano/Micro Formulations
  • Drug-eluding Stents: What Now?
Nov 8-9, 2007

Dr. Ronald T. Borchardt
Solon E. Summerfield Distinguished Professor of Pharmaceutical Chemistry, The University of Kansas

  • Drug Design with Biopharmaceutics in Mind: A Paradigm Shift in Drug Discovery
  • The Challenges of Designing Cyclic Prodrugs of Opioid Peptides that Permeate the Intestinal Mucosa and the Blood-Brain Barrier
Nov 30-Dec 1, 2006

Dr. Allan S. Myerson
Philip Danforth Amour Professor of Engineering and the Provost & Senior Vice President, Illinois Institute of Technology

  • Crystallization Process Development in the Pharmaceutical Industry
  • Nucleation Mechanism and Its Role in the Polymorphic Outcome of Solution Crystallization
May 18-19, 2006

Dr. Jindrich "Henry" Kopecek
Distinguished Professor of Bioengineering and Distinguished Professor of Pharmaceutics & Pharmaceutical Chemistry, Department of Bioengineering, University of Utah

  • Water-soluble Polymers for Cancer Therapy: Concept, Clinical Applications, and Future Directions
  • Self-assembly of Graft and Block Copolymers into Stimuli-sensitive Hydrogels
Apr 7-8, 2005

Dr. Stephen R. Byrn
Charles B. Jordan Professor of Medicinal Chemistry, Purdue University

  • Solid State Pharmaceutical Chemistry
  • The Regulated Pharmaceutical Industry in 2010
Apr 8-9, 2004

Dr. Arthur J. Coury
Vice President of Biomaterials Research, Genzyme Corp

  • Sustained Drug Delivery: Advanced Systems, Growing Therapeutic Applications
  • A Biomaterials Career Regrospective: 1976-2004
Oct 17-18, 2002

Prof. C. Russell Middaugh
Aya & Takeru Higuchi Distinguished Professor of Pharmaceutical Chemsitry, Department of Pharmaceutical Chemistry, University of Kansas

  • Stabilizing Vaccines for the Developing World
  • The Polyanion World Hypothesis
Oct 10-11, 2001

Dr. Arthur R. Mlodozeniec
Principal Scientist, TechniPharm Consulting Group, Menlo Park, CA

  • The Formulation and Pharmaceutical Develpoment of Haloperoxidase Enzymes as Hybrid Products for Microbicidal Activity – Physical and Analytical Chemistry and Pharmaceutics
  • Microbicidal Activity and Topical Drug Delivery for Vaginal Microbicides and Surgical & Combat Wounds – Pharmaceutical Control and Stability
Sept 23, 24, 1999

Dr. James L. Wright
Vice President of Pharmaceutical Development, Alkermes Inc., Cambridge, MA

  • Using Injectable Drug Delivery Systems to Iimprove the Treatment of Patients
  • The Effect of Protein Particle Size on Drug Delivery
May 6-7, 1998

Dr. Sung Wan Kim
Professor of Pharmaceutics and Director of the Center for Chemical Delivery Systems, University of Utah

  • Novel Polymers for the Delivery of Macromolecular Drugs and Cells
  • New Polymeric Gene Carriers
Feb 5-7. 1997

Dr. Douwe D. Breimer
Professor of Pharmacology & Therapeutics, Leiden University, Netherlands
Director of Research, The Leiden/Amsterdam Center for Drug Research

  • Drug Transport across the Blood-Brain Barrier
  • Pharmacodynamics of Rate and Time Control in Drug Delivery
Feb 7-8, 1996

Dr. Joseph D. Andrade, Jr.
Professor, Department of Bioengineering, Materials Science, & Engineering, and Department of Pharmaceutics, College of Pharmacy, University of Utah

  • Direct Reading Biosensors: Analytical Chemistry without Instruments
  • Scientists and the Public Understanding of Science
May 3-4, 1994

Dr. William J. Curatolo
Manager, Oral Druge Delivery and Controlled Release Groups, Pfizer Central Research Division

  • Intestinal Permeability Enhancement for Poorly Permeable Drugs: Efficacy and Toxicity
  • Oral Bioavailability Improvement Strategies for Tripeptide Renin Inhibitors
Apr 19, 1993

Dr. Lewis J. Leeson
Distinguished Research Fellow, CIBA-GEIGY Pharmaceuticals

  • Generic Substitution in New Jersey – A New Jersey Drug Utilization Rreview Council Report
  • A Bit of Physical Pharmacy Nostalgia – The Ionization of Tetracyclines
Oct 23-24, 1991

Dr. Elizabeth B. Vadas
Director, Pharmaceutical Research & Development, Merck-Frosst Center for Therapeutic Research

  • The Development of a New Therapeutic Entity: The Search for New Therapies in Respiratory Disease
  • Formulation Development and Bioanalytical Evaluation of MK-886, an Orally Active Leukotriene Biosynthesis Inhibitor
Apr 15-16, 1991

Dr. Robert Langer
Kenneth J. Germeshausen Professor of Chemical and Biochemical Engineering, Massachusetts Institute of Technology

  • Immobilized Enzyme Bioreactors for Removal of Heparin, Bilirubin, an dcholesterol
  • Novel POlymeric Delivery Systems for Drugs and Mammalian Cells
Nov 28-29, 1989

Dr. Felix Franks
Director of the biopreservation Division, Pafra Ltd.

  • Cold Resistance in Living Organisms: What Can We Learn from Nature?
  • The In Vitro Stabilization of Proteins: Science, Engineering, Legislation and Economics
Apr 5-6, 1988

Dr. Russell O. Potts
Manager of the Dermally Applied Drugs (DAD) Group, Pfizer Central Research

  • Statum Corneum Lipids and Skinn Barrier Function: In Vitro and In Vivo Effects
  • Can Epidermal Metabolism Affect Topical Drug Delivery?
Apr 28-29, 1987

Dr. Richard E. Jones
Director of Pharmaceutical Research and Development, Genentech, Inc.

  • Design and Development of Protein Pharmaceuticals
  • Preformulation Characterization of Recombinant Tissue-Type Plasminogen Activator (rt-PA)
Apr 22-23, 1986

Dr. Francis C. Szoka, Jr.
Associate Professor of Pharmacy and Pharmaceutical Chemistry, School of Pharmacy, UC-San Francisco

  • The Role of Bilayer Contact in Membrane Destabilization: Applications to Drug Delivery from pH Sensitive Liposomes
  • The Magic Bullet Revisted – Targeting of Drugs Using Drug Carriers
Apr 22-23, 1985

Dr. Takeru Higuchi
University Regents Professor, School of Pharmacy, University of Kansas

  • Drug Absorption Across the Skin
  • Solubility of Organic Compounds
May 3-4, 1984

Dr. William R. Good
Director, Basic Pharmaceutics Research, Pharmaceuticals Division, CIBA-GEIGY Corporation

  • Pharmaceutics – An Interdisciplinary Discipline
  • Transdermal Drug Delivery – Opportunities in Endocrinology
Feb 21-22, 1983

Dr. Michael J. Pikal
Research Scientist, Lilly Research Laboratories, Division of Eli Lilly and Company

  • Industrial Pharmaceutical Research: Scintific Solutions to Practical Problems
  • Heat and Mass Transfer in the Freeze Drying of Pharmaceuticals
Nov 12-13, 1981

Dr. Felix Theeuwes
Vice President, Product Research and Development, Alza Corporation

  • The Development of Osmotic Pumps
  • Osmotic Pumps as Rate Specified Dosage Forms
Nov 3-5, 1980

Dr. K. C. Kwan
Senior Director, Merck Dohme Research Laboratories

  • Physiological Disposition of Sulindac
  • Durg Interaction as a Pharmacokinetic Tool
  • Methods and Assumptions in Bioavailability Evaluation
Oct 1-3, 1979

Dr. Everett N. Hiestand
Senior Scientist, The Upjohn Company

  • Material Properties That Influence Tableting
  • Time Dependent Properties in Tableting
  • Applications of Powder Flow and Compaction Theory to Tablet Machines